Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908494 | 0.98 | RIPK1 (0.39) | RIPK1LTA4HGAAPDE10ANISCH | |
| SCHEMBL21187104 | 0.76 | NISCH (0.36) | RIPK1LTA4HNISCHHTTMEN1 | |
| SCHEMBL20798386 | 0.76 | PDE10A (0.39) | RIPK1LTA4HPDE10ANISCHMEN1 | |
| SCHEMBL20798385 | 0.76 | PDE10A (0.39) | RIPK1LTA4HPDE10ANISCHMEN1 | |
| SCHEMBL14421731 | 0.75 | CREBBP (0.39) | LTA4HGAA | |
| SCHEMBL3587691 | 0.74 | — | — | |
| SCHEMBL19859198 | 0.74 | RIPK1 (0.41) | RIPK1LTA4HGAAHPGDTSHR | |
| SCHEMBL5466546 | 0.73 | GAA (0.57) | GAANISCHHPGDHTTSMN1; SMN2 | |
| SCHEMBL28857808 | 0.73 | — | — | |
| SCHEMBL27529870 | 0.72 | RIPK1 (0.35) | RIPK1LTA4HNISCHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | RIPK1 1692/4885LTA4H 340/4885GAA 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.